Who makes VTX3232 Dose A?

VTX3232 Dose A is developed by Zomagen Biosciences Ltd..

Last reviewed 2026-04-19 · How we verify

VTX3232 Dose A

Zomagen Biosciences Ltd. · Phase 2 active Small molecule

At a glance

Generic name	VTX3232 Dose A
Sponsor	Zomagen Biosciences Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity (PHASE2)
Phase 2a Study of VTX3232 in Parkinson's Disease (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VTX3232 Dose A CI brief — competitive landscape report
VTX3232 Dose A updates RSS · CI watch RSS
Zomagen Biosciences Ltd. portfolio CI